Autophagy

Autophagy is an intracellular catabolic mechanism. In certain stressful situations, lysosomes degrade degenerated, damaged, aged or non-functional cells, organelles and biomolecules such as proteins and nucleic acids to achieve cellular protection and organelles from cell damage. Autophagy is achieved by forming a bilayer membrane structure in the cytoplasm that wraps the material to be removed and transports it to the lysosome for degradation. In multicellular organisms, newly formed autophagic vesicles form autophagic endosomes by fusing with vesicles in different stages of the endocytic lysosomal pathway, such as early endosomes and late endosomes, before fusing with lysosomes, a process known as autophagic vesicle maturation. Abnormalities in autophagosome maturation, which is precisely regulated by cellular trophic state and stress signaling pathways, lead to the accumulation of large amounts of damaged organelles and toxic protein aggregates in cells.

Cat. No.	Product name
BP12518	TA-02
BP12518	TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295).
BP12519	VUF11207 fumarate
BP12519	VUF11207 fumarate is an agonist of CXCR7 and a high-potency ligand of CXCR7 (pKi: 8.1).
BP12520	QX77
BP12520	QX77 is a chaperone-mediated autophagy (CMA) activator.
BP12521	LRRK2 inhibitor 1
BP12521	LRRK2 inhibitor 1 is a selective, potent and oral LRRK2 inhibitor with an pIC50 of 6.8 nM.
BP12522	Peiminine
BP12522	Peiminine is an effective inhibitor for lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury.
BP12523	EN6
BP12523	EN6-mediated ATP6V1A modification decouples the v-ATPase from the Rags, leading to inhibition of mTORC1 signaling, increased lysosomal acidification and activation of autophagy. EN6 clears TDP-43 aggregates, a causative agent in frontotemporal dementia, in a lysosome-dependent manner. EN6 is a small-molecule in vivo activator of autophagy that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal the vacuolar H+ ATPase (v-ATPase).
BP12524	P62-mediated mitophagy inducer
BP12524	P62-mediated mitophagy inducer is a regulator of mitophagy.
BP12525	Proflavine Hemisulfate
BP12525	Proflavine Hemisulfate is the hemisulfate salt form of proflavine, an acridine-derived fluorescent contrast and disinfectant agent that can potentially be used for cellular imaging and antiseptic purposes.
BP12526	KB-R7943 mesylate
BP12526	KB-R7943 mesylate is a widely used inhibitor of the reverse Na+/Ca2+ exchanger (NCXrev) with IC50 of 5.7±2.1 μM.
BP12527	Rupatadine Fumarate
BP12527	Rupatadine Fumarate (UR-12592 Fumarate) is a potent dual PAF/H1 antagonist with Ki of 0.55/0.1 uM.
BP12528	Cabazitaxel
BP12528	Cabazitaxel is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after failure of docetaxel.
BP12529	FAAH-IN-2
BP12529	FAAH-IN-2 is a potent inhibitor of FAAH(fatty acid amide hydrolase).
BP12530	3PO
BP12530	3PO is a small-molecule inhibitor of PFKFB3 (IC50: 22.9 μM), inhibiting the proliferation of several human malignant hematopoietic and adenocarcinoma cell lines (IC50: 1.4-24 μM). It suppresses glucose uptake, and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+, and NADH.
BP12531	AMD 3465 hexahydrobromide
BP12531	AMD 3465 hexahydrobromide is a CXCR4 receptor antagonist with potential anticancer and anti-HIV activity.
BP12532	Ambroxol
BP12532	Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the respiratory tract which play an important role in the body's natural defense mechanisms. It stimulates synthesis and release of surfactant by type II pneumocytes. Surfactants act as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.
BP12533	CXCR2-IN-1
BP12533	CXCR2-IN-1 has a pIC50 of 9.3 and is a CXCR2 antagonist of the central nervous system penetration agent.
BP12534	ML327
BP12534	ML327 is a blocker of MYC which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).
BP12535	sbp-7455
BP12535	SBP-7455 potently inhibited ULK1/2 enzymatic activity in vitro and in cells, reduced the viability of TNBC cells and had oral bioavailability in mice.
BP12536	NL-1
BP12536	NL-1 is a mitoNEET inhibitor with antileukemic effect.
BP12537	Streptozocin
BP12537	Streptozotocin is an antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.